Hrt Financial LP Athenex, Inc. Transaction History

Hrt Financial LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	BUY	$0.12 - $0.21 $1,367 - $2,393	11,396 New	11,396 $1,000
Q2 2022 Aug 12, 2022	BUY	$0.41 - $0.91 $13,523 - $30,016	32,985 New	32,985 $13,000
Q1 2022 May 16, 2022	SELL	$0.79 - $1.59 $121,712 - $244,966	-154,067 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$1.36 - $2.94 $482,491 - $1.04 Million	-354,773 Reduced 69.72%	154,067 $209,000
Q3 2021 Nov 15, 2021	BUY	$2.97 - $4.84 $1.51 Million - $2.46 Million	508,840 New	508,840 $1.53 Million
Q4 2020 Feb 16, 2021	SELL	$11.06 - $14.01 $371,914 - $471,114	-33,627 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$10.26 - $14.55 $345,013 - $489,272	33,627 New	33,627 $406,000

1.46M

Ticker ATNX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 156,790,000
Market Cap $1.57M
Description
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar,...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.